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Abstract
Background: Therapeutic management of upper extremity (UE) function of boys and men with Duchenne
Muscular Dystrophy (DMD) requires sensitive and objective assessment. Therefore, we aimed to measure
physiologic UE function of healthy subjects and DMD patients in different disease stages, and to evaluate the
relation between these physiologic measures and functional UE scales.
Methods: Twenty-three DMD patients and twenty healthy controls (7–23 years) participated in this explorative
case–control study. Maximal muscle torque, maximal and normalized surface electromyography (sEMG) amplitudes,
muscle thickness, echogenicity and maximal passive and active joint angles were measured. At activity level, Brooke
upper extremity rating scale and the Performance of Upper Limb (PUL) scale were used.
Results: Outcome measures related to proximal UE function could discriminate between disease stages. Increased
normalized sEMG amplitudes were found in patients, even in early disease stages. Maximal active joint angles
showed the strongest relation to Brooke scale (R2 = 0.88) and PUL scale (R2 = 0.85).
Conclusions: The decline of muscle functions precedes the decline in performance of UE activities, and therefore
may play a role in early detection of UE limitations. Increased sEMG levels demonstrate that DMD patients use more
of their muscle capacity compared to healthy subjects, to perform daily activities. This might result in increased
fatigability. Active maximal joint angles are highly related to functional scales, so preserving the ability to use the
full range of motion is important for the performance of daily activities. Close monitoring of active joint angles
could therefore help in starting interventions that minimize functional UE decline in DMD patients timely.
Keywords: Duchenne muscular dystrophy, Upper limb, 3D motion analysis, Surface electromyography,
Muscle ultrasound, Muscle torque
Background
Duchenne Muscular Dystrophy (DMD) is a x-linked
neuromuscular disorder with an incidence of 1:5,000
male newborns [1]. The disorder is characterized by a
progressive loss of muscle strength, starting in the pelvic
girdle, however, in later stages all muscles become
affected. Boys with DMD become non-ambulant around
the age of 10 years when untreated, and around the age
of 13 years when treated with corticosteroids [2]. Arm
function is already affected at this age [3, 4]. Although
there is no curative treatment for DMD, life expectancy
is rapidly increasing due to medical interventions [5, 6].
This means that boys and men with DMD have to live
longer with their functional limitations and thus main-
taining upper extremity (UE) function and measuring
changes in UE function are increasingly important.
Loss of UE function can be delayed by several years by
using corticosteroid treatment [7–10]. Physical exercise
programs have also been found to be beneficial for
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retaining UE function [11–13]. However, in the long
term, interventions that compensate for loss of UE func-
tion are still needed, for example arm supports, which
reduce the effort that is needed to perform activities. To
develop and evaluate such interventions, more insight
in the upper extremity is needed. Insights on both
International Classification of Functioning, Disability and
Health (ICF) [14] function and structure level, and ICF
activity level are necessary in order to unravel the mecha-
nisms of UE decline.
The primary aim of this study is to give a quantitative
description of UE functioning during a variety of mean-
ingful UE task in boys and men with DMD in different
stages of the disease, in comparison to their healthy
peers. The secondary aim is to evaluate the relation
between physiologic and structural UE functions and
functional UE scales.
Methods
Population
The study population consisted of 23 boys and men with
DMD and 20 healthy boys and men. DMD patients were
included if they were older than 6 years, had a DNA
established DMD diagnosis, and had a Brooke scale [15]
of 1–5, meaning that they were able to use their hands
functionally. Patients were recruited through the Radboud
University Medical Center (Radboudumc) outpatient
clinic and by an advertisement on the website of the
Dutch DMD patient organization (“Duchenne Parent
Project”). Healthy subjects over 6 years, without UE
mobility limitations, were included from schools in the
neighborhood of the Radboudumc in the city of Nijmegen.
This study was approved by the medical ethical com-
mittee Arnhem–Nijmegen, the Netherlands (Registration
number 2012/135, NL nr.: 39126.091.12). Informed con-
sent was obtained from all participants and from their par-
ents when the subjects were under 18 years of age.
Outcome measures
Participant characteristics
The following participant characteristics were collected
based on self-reports: age, arm preference, weight,
height, year of diagnosis, wheelchair confinement and, if
applicable the age of wheelchair confinement, and the
occurrence of scoliosis.
Functional UE scales
Functional UE scales used in this study were: “Brooke
upper extremity rating scale [15]” and the “Performance
of Upper Limb (PUL) scale [16]”. These functional scales
measured participants’ activity level. PUL items were
performed once. Based on the score of the entry item,
some subjects only performed a specific subset of the
PUL. Sum scores of the 3 dimensions (high level
shoulder, mid level elbow, distal wrist and hand) and the
total sum score were calculated.
Muscle torques and surface electromyography
Muscle torques and surface electromyography (sEMG)
signals were recorded of 7 different upper extremity
muscles (Trapezius (descending part), Biceps Brachii
(long head), Triceps Brachii (long head), Deltoid (lateral
part), Pectoralis Major (clavicular head), wrist flexors
and wrist extensors). Muscle torques were measured
using a static frame myometer, consisting of a KAP-E
Force Transducer, measurement range 0.2–2000 N
(Angewandte System Technik, Dresden, Germany), and
a height and position adjustable frame (designed and
custom made by mechanical engineers from the VU med-
ical centre, Amsterdam, the Netherlands). Wireless sEMG
signals (Zerowire EMG, Aurion, Italy) were recorded with
a sample frequency of 1000 Hz. Disk-shaped Ag–AgCL
ARBO ECG electrodes (Tyco Healthcare, Neustadt,
Germany) were placed at an inter electrode distance of
24 mm. Testing and electrode positions were based on lit-
erature [17, 18]. To make the measurement protocol more
suitable for DMD patients, as they were often in a wheel-
chair or had joint contractures, we slightly adapted some
of the testing positions. sEMG data were filtered using a
4th order band pass filter between 20 and 450 Hz, where
after the signal was rectified and low pass filtered (3 Hz)
to obtain the linear envelope [19, 20]. Torque data were
filtered using a 3 Hz low pass filter of the 4th order.
All subjects performed two maximal voluntary isometric
contractions (MVICs) to determine the maximal muscle
torque and corresponding sEMG amplitude. If the exam-
iner was not confident that a maximal effort was made,
the measurement was repeated. The maximal value out of
the two correct attempts was used for further data ana-
lysis. Normalized sEMG amplitudes were calculated for
the performance of single joint movements and PUL
items. Normalized sEMG amplitude was defined as the
maximum sEMG amplitude that was reached during a
movement as a percentage of the maximal amplitude of
the same muscle during MVIC.
Data was processed with custom-written Matlab (Matlab®
version R2014b, Mathworks, Natick, USA) routines.
Quantitative muscle ultrasound
Ultrasounds images of 6 upper extremity muscles
(Trapezius, Biceps Brachii, Triceps, Deltoid, wrist flexors
and wrist extensors) were recorded using a Z.One PRO
Ultrasound System (Zonare Medical Systems, Mountain
View, California, USA), with a L10-5 transducer. Three
ultrasound recordings were made, at a depth of 4 cm, to
calculate echogenicity (greyscale) and one recording,
with no predefined depth, was made to determine the
muscle thickness. Echogenicity is the extent to which a
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structure reflects ultrasound of a surface with high echo-
genicity indicating that more ultrasound is reflected, for
example when high levels of fatty and connective tissue
are present in a muscle. Ultrasound images were
analyzed with computer-assisted greyscale histogram ana-
lysis, using custom software developed at Radboudumc
(QUMIA). Echogenicity was determined by calculating
the grayscale in the upper 1/3rd of the region of interest
(the region that included as much muscle mass as possible
without bone and fascia) in each muscle [21]. The average
echogenicity out of 3 measurements was used for further
analysis. Muscle thickness was determined by calculating
the distance between two electronic calipers at standard-
ized positions. Thickness of the Trapezius was measured
between the deep and superficial fascia of the upper part
of the Trapezius muscle. Thickness of the Deltoid, Biceps
(combined with Brachialis) and Triceps muscles were
measured between the humerus and the superficial fascia.
Forearm flexor (Flexor Carpi Radialis) thickness was mea-
sured between a horizontal reference line at the height of
the radius and the superficial fascia. Forearm extensors
thickness was measured between the middle end of the ra-
dius and the superficial fascia.
Ultrasound results were compared to muscle specific
reference values and expressed as Z-scores (representing
the number of standard deviations from the mean) [22].
Reference values for calculation of the Z-scores were
obtained from 60 healthy subjects using the same meas-
urement protocol and ultrasound device (manuscript in
preparation). Echogenicity and muscle thickness were
corrected for age, weight and height if necessary using
the method described by Scholten et al. [23].
Three dimensional motion analysis
Three dimensional motion analysis, using the kinematic
model of Jaspers et al. [24] (Fig. 1), was performed with
an 8 camera VICON motion analysis system (Oxford
Metrics, Oxford, UK). After marker placement and ana-
tomical landmark identification, maximal passive joint
angles were determined for: ‘shoulder abduction’, ‘elbow
flexion and extension’, ‘pro- and supination of the lower
arm’, ‘wrist flexion and extension’ and ‘wrist ulnar and
radial deviation’. Maximal active joint angles were
determined for the same movements and also for ‘shoulder
flexion’ and ‘shoulder adduction (in the horizontal plane)’
(Fig. 2). Some subjects did not perform all single joint
movements as they were unable to perform the move-
ments. All passive and active movements were performed
3 times at a controlled movement velocity.
Joint-kinematics were calculated using BodyMech
(http://www.bodymech.nl) and additional custom-written
Matlab routines. Kinematic data were filtered using a 4th
order low pass filter of 20 Hz. Per movement, the minimal
and maximal joint angles were determined. The average
maximal joint angle over three measurements was used
for further data analysis.
Statistical analysis
Median values and ranges were used to describe the
continuous participant characteristics and percentages
were used to describe categorical participant characteris-
tics. Wilcoxon rank sum tests were used to compare
outcome measure sum scores between healthy subjects
and DMD patients. Kruskal-Wallis tests were used to
test for differences between DMD patients in different
Brooke scales. To gain insight in the relation between
functional UE scales (Brooke and PUL scale) and physio-
logic UE function (muscle torque, sEMG, echogenicity,
muscle thickness, passive and active joint angles) we cal-
culated the coefficient of determination (R2) between the
sum scores, or average scores for echogenicity and
muscle thickness, of these outcome measures. The sum
scores were calculated by adding the results of all values
within one outcome measure. If one or more values were
missing, the sum score was also reported as missing. If
values were missing because patients were physically un-
able to perform the activity a score of 0 was used for the
calculation of the sum scores. SPSS Statistics Version 20
(IBM, Somers, USA) was used for statistical analysis.
Results
The median age of healthy subjects was 14.0 (range
7.4–23.4) years and the median age of DMD patients was
14.9 (range 8.1–21.7) years (Table 1). About 90% of the
participants was right handed. The median age at diagno-
sis was 3.75 years (range 0–7 years) and 74% of the
patients was non-ambulant. Thirteen percent of the
patients had a mild scoliosis, and 22% had a severe
Fig. 1 Marker positions. Positions of cluster markers (black center)
and anatomical landmarks (white center)
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scoliosis, of which 40% was surgically corrected. Cortico-
steroids were used by 74% of the patients, while 13%
stopped using and 13% never used corticosteroids. Of the
corticosteroid users, 12% used Deflazacort on a daily basis
and 88% uses Prednisone/Prednisolone on a 10-days-on/
10-days-off basis. Dosages vary between 4 and 45 mg.
Statistically significant differences between healthy
subjects and DMD patients were seen in all outcome
measures except muscle thickness, as all the Z-values for
muscle thickness were between −2 and 2 (Table 2). In
addition, differences between patients in different
Brooke scales were present in most proximal muscles
Fig. 2 Single joint movements. a shoulder flexion, (b) shoulder abduction, (c) shoulder adduction (in the horizontal plane), (d) elbow flexion and
extension, (e) forearm pronation and supination, (f) wrist flexion and extension and (g) wrist ulnar and radial deviation
Table 1 Participant characteristics
Variable Healthy DMD Brooke 1 DMD Brooke 2 DMD Brooke 3 DMD Brooke 4 DMD Brooke 5
N 20 5 8 4 3 3
Age (median, range) 14.0 (7.4–23.4) 11.1 (8.0–16.0) 12.4 (8.7–15.8) 15.8 (12.6–16.9) 17.1 (17.0–18.4) 18.2 (17.8–21.7)
BMI 19.1 (15.7–24.4) 21.9 (17.7–26.4) 20.7 (18.7–30.8) 23.0 (16.5–26.0) 17.6 (10.0–21.4) 22.5 (19.4–24.6)
Hand preference
Right handed (%) 90 100 87.5 75 100 100
Left handed (%) 10 0 12.5 25 0 0
Age of diagnosis (median, range) - 2.0 (0.0–5.0) 4.0 (2.5–7.0) 4.0 (2.5–6.0) 1.5 (0.0–6.0) 1.0 (0.0–6.0)
Percentage wheelchair confined (%) - 0 87.5 100 100 100
Age wheelchair confined (median, range) - - 10 (7–13) 10 (8–10) 11 (10–11) 9 (8–10)
Scoliosis
No (%) - 75 87.5 75 33 0
Mild (%) - 25 12.5 0 0 33
Severe (%) - 25 67 67
Scoliosis correction (%) - 0 0 0 33 67
Corticosteroid use
No (%) - 0 12.5 25 33 0
Not anymore (%) - 0 0 25 0 67
Yes (%) - 100 87.5 50 67 33
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and movements requiring proximal muscles. PUL scores
in all domains differed between DMD patients in
different Brooke scales.
Normalized sEMG amplitudes of DMD patients and
healthy controls differed significantly for all movements
and muscles, except for Trapezius activation during
shoulder abduction (Fig. 3). Maximal active joint angle
sum score shows the strongest correlations with Brooke
scale (Fig. 4) and PUL score (Fig. 5) (R2 of 0.88 and 0.85
respectively), followed by maximal muscle torque and
maximal sEMG amplitude sum scores (R2 > 0.5). Echo-
genicity and passive maximal joint angle sum scores
explain about 30% of the variance of Brooke scale and
PUL score.
In healthy subjects, a strong relation with age was
present for maximal muscle torque sum score and mean
muscle thickness z-score (Fig. 6, R2 of 0.79 and 0.86 re-
spectively). For DMD patients the strongest correlations
with age were found for maximal active joint angle sum
score and Brooke scale (R2 of 0.64 and 0.63 respectively).
Discussion
Our study provides new insights in the muscles and
movements that are affected most in DMD patients, and
how this relates to functional UE scales. This is vital
information for clinical decision making, but can also be
used in the development of new outcome measures in
clinical trials.
Currently, functional scales such as the Performance
of Upper Limb (PUL) scale and the Motor Function
Measure (MFM) are used as the gold standard for quan-
tifying UE limitations in DMD. These measures, how-
ever, are not able to cover the entire spectrum of DMD
patients, as they have floor and ceiling effects [16]. Fur-
thermore, they do not give insight in the underlying
working mechanisms of the UE. Daily activities require
sufficient strength of multiple muscle groups and mo-
tion in multiple joints. Therefore, functional scales give
insight in problems that result from a combination of
many different physiologic aspects of UE function.
Our study shows that muscle functions (i.e. maximal
muscle torque, maximal sEMG amplitude and echogeni-
city z-scores) of DMD patients already deviate from
healthy subjects in an early disease stage (i.e. Brooke 1). A
similar reduction of muscle force/torque in young DMD
patients has been reported in previously [3, 25–27]. Echo-
genicity z-scores of all muscles are above two thus differ
significantly from the healthy reference population. This
finding indicates that muscles are infiltrated with fatty and
connective tissue, which is in line with the results of other
studies [21, 28, 29]. Consequently, these outcome mea-
sures are of great importance for early detection of UE
Fig. 3 Normalized sEMG amplitudes. Normalized sEMG amplitudes of the Trapezius, Deltoid and Biceps Brachii muscles for 6 different upper
extremity movements shown for healthy subject and DMD patients in different Brooke scales. Sho Abd = shoulder abduction; Elb Flex = elbow
flexion; Reach Forward = reaching forward at shoulder level without weight (PUL item D); Drink = drinking from a full cup (200 g) (PUL item F);
Move Weight =moving a 100 g weight (PUL item H); Trace Path = tracing a path (PUL item O)
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impairments, as activity scales cannot be used in the
earliest disease stage due to ceiling effects. Early detection
is important to start interventions early, for example phys-
ical exercise training, which is proven to be effective in
delaying functional deterioration [11–13]. The current
study shows that mainly proximal muscles and move-
ments requiring proximal muscle activation are sensitive
to detect differences of UE function and activity. Maximal
muscle torques and maximal sEMG amplitudes of prox-
imal muscles can also detect differences in the later
disease stages (Brooke 4 and 5), even though the muscles
cannot initiate movements anymore. This could be
important for evaluating the effects of arm supports, or
other interventions aimed at late stage DMD patients.
To identify which limitations are primarily responsible
for the inability to perform activities, and how this re-
lates to weakness in specific muscles, insight in single
joint movements is important. Single joint movements
consist of movements over one joint, which often can be
related to the activation of one primary muscle. In clin-
ical practice, the measurement of maximal active single
joint angles can give more insight in the mechanism re-
sponsible for activity limitations. This statement is sup-
ported by the very strong relation we found between
maximal active joint angles and PUL score (R2 = 0.85).
Our results show that when the maximal Deltoid
torque drops below approximately 10 Nm, DMD pa-
tients start to have difficulties lifting their arms. A max-
imal Biceps torque below approximately 5 Nm is related
to restrictions in elbow motion. It is likely these are the
minimum torques required to move the upper/lower
arm against gravity, and could help to identify the suit-
able time to start using an arm support. Hence, regular
assessment of deltoid and biceps torques may help clini-
cians plan interventions, anticipating functional decline.
We found that active and passive joint angles decline
almost simultaneously. Therefore, we hypothesize that
when a patient loses the ability to move a joint actively,
Fig. 4 Correlations with Brooke scale. Correlations of DMD patients between Brooke score and (a) maximal muscle torque sum score; b maximal
sEMG amplitude (MVIC) sum score; c mean inverse z-score of echogenicity (inverse z-scores were used so that lower scores indicate worse UE
function); d mean z-score of muscle thickness; e maximal passive joint angle sum score; f maximal active joint angle sum score
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the joint will be statically positioned for longer periods,
which leads to contractures soon thereafter. This hy-
pothesis is in line with the findings of McDonald et al.
who showed the occurence of elbow flexion contractures
appears to be related to static positions of the limb after
wheelchair confinement [30]. Hence, we recommend to
start interventions, such as stretching exercises, as soon
as active joint angles start to decrease. In addition, we
recommend stimulation of (supported) movement to
limit static positioning and thereby prevent contracture
formation [31].
A recent study has indicated that fatigue was strongly
associated with health-related quality of life and that
there should be a greater clinical focus on the reduction
of fatigue [32]. In this study, we measured maximal
sEMG amplitudes, which is a measure for the maximal
muscle capacity. Normalized sEMG amplitudes show
the percentage of this maximal muscle capacity needed
to perform activities. When normalized sEMG amplitudes
are high, a larger percentage of the muscle capacity is
used, which leads to faster occurrence of fatigue [33].
Our results show that DMD patients use a larger per-
centage of their muscle capacity to perform movements
and activities compared to healthy subjects, even in an
early stage of the disease, and therefore might experi-
ence earlier and more fatigue. This increase in the
percentage of muscle capacity is not only seen in prime
movers, but also in secondary movers indicating the use
of compensatory muscles to overcome loss of muscle
strength. Future studies should try to determine
normalized sEMG amplitudes and normalized sEMG
median frequency during a fatigue protocol, in order to
gain more insight in muscle fatigue of DMD patients
compared to healthy controls.
Although most of our results are in line with existing
literature, we also found some differences. The passive
forearm supination angle of DMD patients in this study
did not differ significantly (p = 0.072) from healthy
Fig. 5 Correlations with PUL score. Correlations of DMD patients between total PUL score and (a) maximal muscle torque sum score; b maximal
sEMG amplitude (MVIC) sum score; c mean inverse z-score of echogenicity (inverse z-scores were used so that lower scores indicate worse UE
function); d mean z-score of muscle thickness; e maximal passive joint angle sum score; f maximal active joint angle sum score
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subjects, as opposed to findings from Bartels et al. [27].
However, we found that the average forearm supination
angles were reduced in patients from Brooke 3 onward,
which is in line with the results of Bartels et al. who re-
ported that 83% of the adult men with DMD had loss of
supination [27]. As far as we are aware, the differences we
found between healthy subjects and DMD patients for
passive elbow flexion, forearm pronation, wrist flexion
and ulnar deviation have not been reported before.
Although the differences between healthy subjects and
DMD patients are small, they could be of clinical rele-
vance for the performance of daily UE activities [34–36].
Muscle ultrasounds are able to make distinction be-
tween different stages of DMD [21, 28] We, however,
found that echogenicity is less strongly related to disease
stage compared to maximal muscle torque and maximal
Fig. 6 Correlations with age. Correlations of DMD patients and healthy subject between age and (a) Brooke scale; b total PUL score; c maximal
muscle torque sum score; d maximal sEMG amplitude (MVIC) sum score; e mean inverse z-score of echogenicity (inverse z-scores were used so
that lower scores indicate worse UE function); f mean z-score of muscle thickness; g maximal passive joint angle sum score; h maximal active joint
angle sum score
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sEMG amplitude. We expect that echogenicity, which is
a measure for muscle degeneration, is less discriminative
in the explored muscles because the ultrasound images
are heavily affected by attenuation. This is especially true
for the later disease stages, as an increased amount of fat
and connective tissue in the muscles prevents the ultra-
sound from penetrating deeper layers of the muscle,
which results in a darker picture and therefore lowers Z-
scores. For the same reason muscle thickness could not
be measured accurately in older patients.
Study limitations
A limitation of this study is the relatively small number of
patients in each group, especially in the latest disease
stages. For this reason, post hoc comparisons between
different disease stages were not performed. Furthermore,
stratification of possible confounders, such as corticoster-
oid use and scoliosis, was not possible due to the small
sample size. In addition, as this study is cross-sectional,
we were unable to determine longitudinal changes of UE
function. Therefore we recommend future UE studies to
monitor changes of physiologic UE function over time in
a cohort of patients. Nevertheless, our population is repre-
sentative of the general DMD population, as the partici-
pant characteristics are comparable to literature.
A second limitation relates to our measurements of
individual muscle strength. External muscle torque
measurements, as we performed with the static frame
myometer are unable to measure the maximal torque of
isolated muscles. We attempted to mimic the activation
of individual muscles as close as possible by choosing
measurement positions that primarily required the acti-
vation of one muscle, the prime mover. We reported
muscles torques as our primary outcome rather than
muscle forces, which are more commonly used in litera-
ture. Muscle forces, however, do not account for the
effect of lever arm, which we believe is more relevant in
our study as we measured subjects in a wide age/height
range [37]. For comparability we also reported maximal
muscle forces in Table 2.
Finally, the use of normalized sEMG amplitudes has
some limitations as well . The maximal sEMG amplitude
(in MVIC) can be influenced by pain, fear of pain, restric-
tions in the range of motion and/or motivation [18]. As a
result normalized sEMG amplitudes over 100% MVIC
were sometimes seen. This underperformance during
MVIC measurements could affect both healthy subject
and patients. However, in patients, pain might be of
greater influence due to joint contractures. The obtained
results, however, show large differences between healthy
boys and DMD patients, which cannot be attributed solely
to underperformance.
Despite these limitations, we think this study gives
valuable and objective insights in UE function and
activity level of boys and men with DMD, which are of
great clinical importance for the selection and evaluation
of suitable interventions.
Conclusions
The decline of muscle functions precedes the decline in
performance of UE activities, and therefore may play a
role in early detection of UE limitations. Early detection
can have important clinical implications as it allows for
starting interventions, such as contracture prevention
and physical exercise training, timely and minimize
functional decline. Increased sEMG levels demonstrate
that DMD patients use more of their muscle capacity
compared to healthy subjects to perform daily activities.
This might result in increased fatigability, which should
receive attention in clinical practice as this is an import-
ant determinant of quality of life. Active maximal joint
angles are highly related to functional scales, therefore
preserving the full range of motion is important in daily
life. Monitoring active joint angles can help to select
appropriate interventions timely, to minimize UE decline.
Finally, the results of this study can be used for the devel-
opment of new composite outcome measures for clinical
trials, that not only aim at the ICF activity level, but also
on the ICF level of body functions and structures.
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